Evidence map›Paper›PMID 42797288›Full record

ArticlePharmaceutics2026

Pyridoxic Acid as a Novel Endogenous Biomarker for OAT-Mediated Clearance of Meropenem: A Population Pharmacokinetic Modeling and PK/PD-Response Analysis in Patients with Sepsis.

Zihan Lei, Hao Liang, Qin Cheng, Weijie Kong, Yipeng Du, Xueting Yao, Feifei Feng, Yuyan Jin, Wenting Wang, Haiyan Li and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zihan LeiDepartment of Pulmonary and Critical Care Medicine, Peking University Third Hospital, Beijing 100191, China.
Hao LiangDrug Clinical Trial Center, Peking University Third Hospital, Beijing 100191, China.ORCID 0000-0003-4382-3704
Qin ChengDepartment of Pulmonary and Critical Care Medicine, Peking University Third Hospital, Beijing 100191, China.
Weijie KongDrug Clinical Trial Center, Peking University Third Hospital, Beijing 100191, China.
Yipeng DuDepartment of Pulmonary and Critical Care Medicine, Peking University Third Hospital, Beijing 100191, China.
Xueting YaoDrug Clinical Trial Center, Peking University Third Hospital, Beijing 100191, China.
Feifei FengDrug Clinical Trial Center, Peking University Third Hospital, Beijing 100191, China.
Yuyan JinDrug Clinical Trial Center, Peking University Third Hospital, Beijing 100191, China.
Wenting WangDepartment of Pulmonary and Critical Care Medicine, Peking University Third Hospital, Beijing 100191, China.
Haiyan LiDrug Clinical Trial Center, Peking University Third Hospital, Beijing 100191, China.
Ming LuDepartment of Pulmonary and Critical Care Medicine, Peking University Third Hospital, Beijing 100191, China.
Dongyang LiuDrug Clinical Trial Center, Peking University Third Hospital, Beijing 100191, China.ORCID 0000-0002-0608-8192
Ning ShenDepartment of Pulmonary and Critical Care Medicine, Peking University Third Hospital, Beijing 100191, China.

Funding

National Natural Science Foundation of China 82204522Peking University Third Hospital BYSYZD2022007Peking University Third Hospital BYSYZD2024022
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

meropenemOAT transporterspharmacokinetic/pharmacodynamicprecision medicinepyridoxic acidsepsistranslational biomarker

Identifiers

PMID42797288
PMCPMC13610781

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.